Pneumonia is a bacterial lung infection caused by entering of the bacteria into the lungs’ small air sacs called Alveoli. When the body creates white cells to fight the infection Alveloi get filled with white fluid, called pus which creates Pneumonia.
Doxycycline has proved to have a good history of treatments with all respiratory diseases, specifically the lower tract disease such as pneumonia. There are quite a few clinical trials detailing the success of doxycycline in community-acquired pneumonia. One such test was conducted to find out about the effectiveness of the medicine in mild to mildly severe cases of community acquired Pneumonia, as an empirical intravenous medicine treatment to be given in hospitalised patients. 87 patients were split into two groups. One, who were given 100mg of Doxycycline as an intravenously every twelve hours and the remaining group of forty three people were given other competitor medicines.
The results not only showed early recovery symptoms in the patients consuming Doxycycline, also proved to be a far more cost effective treatment compared to the control group treated with a range of antibiotics. The Doxycycline group needed lesser days and lesser costs of hospitalisation and the treatment costs were considerably lower too. For detailed information on the study you may refer to http://archinte.ama-assn.org/cgi/content/full/159/3/266